Cost of Revenue Comparison: Biogen Inc. vs Bausch Health Companies Inc.

Cost of Revenue: A Tale of Two Giants

In the competitive landscape of the pharmaceutical industry, understanding cost structures is crucial. This chart provides a fascinating comparison of the cost of revenue for Biogen Inc. and Bausch Health Companies Inc. over the past decade. From 2014 to 2023, Bausch Health consistently reported higher costs, peaking in 2015 with a 17% increase from the previous year. Meanwhile, Biogen's cost of revenue showed a steady upward trend, culminating in a 116% rise by 2023 compared to 2014.

Key Insights

• Bausch Health: Despite fluctuations, their cost of revenue remained relatively stable, with a slight dip in 2018.
• Biogen: Demonstrated a more dynamic growth, with significant increases in 2021 and 2022.
  This data not only highlights the operational strategies of these companies but also reflects broader industry trends, offering valuable insights for investors and analysts alike.